Additional Post‐BALB/cnu/nu hosts were established as described above and injected three times around 231‐tumor challenges with neutralizing mAb of anti‐αβTCR, anti‐Vγ1TCR/‐Vγ4TCR, or anti‐CD28, with normal IgG as control Ab to see if ETSB‐primed peripheral defense axis revival would be deterred by TCR blockade (Figure S8A, Supporting Information). Here, CD28 is linked to neoplasm.